Quanterix Corporation (NASDAQ:QTRX) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.42 per share.
For the full year, analysts predict revenues of $ 61.64 million, while looking forward to loss of $ 1.69 per share.
Previous Quarter Performance
Quanterix Corporation reported loss for the second quarter of $ 0.43 per share, from the revenue of $ 13.13 million. Wall street analysts are predicting, QTRX to report 2Q20 loss of $ 0.44 per share from revenue of $ 15.01 million. The bottom line results beat street analysts by $ 0.01 or 2.27 percent, at the same time, top line results fell short of analysts by $ 1.88 million or 12.52 percent.
Stock Performance
Shares of Quanterix Corporation traded up $ 2.77 or 7.05 percent on Wednesday, reaching $ 42.07 with volume of 251.80 thousand shares. Quanterix Corporation has traded high as $ 42.66 and has cracked $ 39.40 on the downward trend
The closing price of $ 42.07, representing a 260.55 % increase from the 52 week low of $ 10.90 and a 19.71 % decrease over the 52 week high of $ 48.95.
The company has a market capital of $ 1.32 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 19th October 2020, maintained by SVB Leerink at Outperform rating, with $ 48.00 target price.
- On 6th October 2020, maintained by Canaccord Genuity at Buy rating, with $ 40.00 target price.
Conference Call
Quanterix Corporation will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.quanterix.com
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays.
